Buforin II, derived from buforin I, a protein isolated from the stomach of the Asian toad Bufo bufo gargarizans, is a potent antimicrobial peptide. Buforin II has antimicrobial activity against a broad spectrum of Gram-positive and Gram-negative bacteria[1].
Buforin II inhibits A. baumanniiATCC 19606 and multiresistant strains with the similar MIC values of 8 mg/L[1].
Buforin II (intravenously a single dose, 1 mg/kg) has potent antibacterial activity that effectively reduces lethality and leads to a significant reduction in plasma endotoxin and cytokine concentrations in male Wistar rat model of sepsis[1].
| Animal Model: | Male Wistar rats weighing 200 to 300 g with A. baumannii ATCC 19606[1] |
| Dosage: | 1 mg/kg |
| Administration: | Intravenously a single dose |
| Result: | Reduced mortality by 40% in the treatment group and by 20% in the rifampicin (10 mg/kg) combination group. Reduced TNF, IL-6 and endotoxin plasma levels by 33%, 25% and 32%, respectively. |
| Animal Model: | Male Wistar rats weighing 200 to 300 g with the multiresistant strain[1] |
| Dosage: | 1 mg/kg |
| Administration: | Intravenously a single dose |
| Result: | Reduced mortality by 46.6% in the treatment group and by 20% in the rifampicin (10 mg/kg) combination group. Reduced TNF, IL-6 and endotoxin plasma levels by 46%, 20% and 28%, respectively. |
[1]. Oscar Cirioni, et al. Therapeutic efficacy of buforin II and rifampin in a rat model of Acinetobacter baumannii sepsis. Crit Care Med. 2009 Apr;37(4):1403-7.